The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First line atezolizumab + bevacizumab (atezo/bev) or durvalumab ± tremelimumab (durva±treme) in unresectable hepatocellular carcinoma (HCC): A real world, multi-institutional retrospective cohort study.
 
Ioannis Kournoutas
No Relationships to Disclose
 
Paulina Marell
No Relationships to Disclose
 
Anina Peersen
Employment - Mayo Clinic
 
Garima Gupta
Stock and Other Ownership Interests - Abbott Laboratories; CUE Biopharma; IIPR; Moderna Therapeutics; Moderna Therapeutics; Roche
 
Mehmet Akce
Consulting or Advisory Role - AstraZeneca; Curio Science; Eisai; Eisai; Eisai; Eisai; Exelixis; Genentech; GlaxoSmithKline; GlaxoSmithKline; Incyte; Ipsen; Isofol Medical; QED Therapeutics; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb-Ono Pharmaceutical (Inst); Eisai (Inst); Eisai (Inst); IMPAC Medical Systems (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Polaris (Inst); ProDa (Inst); RedHill Biopharma (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst); Xencor (Inst)
 
Ju Dong Yang
Consulting or Advisory Role - AstraZeneca; Eisai; Exact Sciences; Exelixis; Fujifilm
 
Pin-Jung Chen
No Relationships to Disclose
 
Nikolas Naleid
No Relationships to Disclose
 
Amit Mahipal
Consulting or Advisory Role - AstraZeneca/MedImmune; Elevar Therapeutics; Guardant Health; Taiho Oncology
Speakers' Bureau - AstraZeneca; Taiho Oncology
Research Funding - Taiho Pharmaceutical
 
Vaibhav Sahai
Consulting or Advisory Role - AstraZeneca; Autem Medical; Delcath Systems; Elevar Therapeutics; Histosonics; Incyte; Ipsen; Jazz Pharmaceuticals; Lynx Group; Rafael Pharmaceuticals; SERVIER; Taiho Oncology
Research Funding - Actuate Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Elicio Therapeutics (Inst); Esanik (Inst); Exelixis (Inst); FibroGen (Inst); Ipsen (Inst); MedImmune (Inst); Pancreatic Cancer Action Network (Inst); Rafael Pharmaceuticals (Inst); Relay Therapeutics (Inst); Relay Therapeutics (Inst); Repare Therapeutics (Inst); SERVIER (Inst); Syros Pharmaceuticals (Inst); TransThera Biosciences (Inst)
Travel, Accommodations, Expenses - ASCO; Lynx Group
Other Relationship - Rafael Pharmaceuticals (Inst)
 
Scott Thompson
Consulting or Advisory Role - Boston Scientific; Boston Scientific
Research Funding - TERUMO
 
Zhaohui Jin
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca (Inst); Elevar Therapeutics (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Lilly (Inst)
 
Sudhakar Venkatesh
No Relationships to Disclose
 
Mitesh Borad
Consulting or Advisory Role - BJ Bioscience; Genentech; Imvax; Kriya Therapeutics; Lynx Group; Merck; Senti Biosciences; Tempus; Zymeworks
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Basilea (Inst); Biond Biologics (Inst); Celgene (Inst); Eisai (Inst); EMD Serono (Inst); Halozyme (Inst); Incyte (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); Kinnate Biopharma (Inst); MedImmune (Inst); Merck Serono (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Qurient (Inst); RedHill Biopharma (Inst); Relay Therapeutics (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Taiho Pharmaceutical (Inst); ZielBio (Inst)
 
Hani Babiker
Consulting or Advisory Role - Celgene; Endocyte; Idera; Myovant Sciences; Novocure
Speakers' Bureau - Guardant Health
 
Tanios Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Caladrius Biosciences; Caladrius Biosciences; Celularity; Daiichi Sankyo/UCB Japan; Deciphera; Eisai; Eisai; Exact Sciences; Foundation Medicine; Foundation Medicine; Illumina; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Kanaph Therapeutics; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Stemline Therapeutics; Treos Bio; Zai Lab
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - 1Globe Health Institute; AstraZeneca; Exelixis; FibroGen; Imugene; Lilly; Merck (Inst); Pancreatic Cancer Action Network; Replimune; Sun Biopharma; Suzhou Kintor Pharmaceuticals; UpToDate; Xilis
 
Robert McWilliams
Stock and Other Ownership Interests - Zentalis
Consulting or Advisory Role - Zentalis
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline/Tesaro (Inst); Merck (Inst); Newlink Genetics (Inst)
 
Thorvardur Halfdanarson
Consulting or Advisory Role - Advanced Accelerator Applications (Inst); Boehringer Ingelheim; Camurus (Inst); Crinetics Pharmaceuticals (Inst); Curium Pharma; Exelixis; Ipsen (Inst); ITM Isotope Technologies Munich (Inst); Perspective Therapeutics (Inst); Tersera; Viewpoint Molecular Targeting (Inst)
Research Funding - Advanced Accelerator Applications (Inst); Camurus (Inst); Crinetics Pharmaceuticals (Inst); ITM Isotope Technologies Munich (Inst); Novartis (Inst); Perspective Therapeutics (Inst); Thermo Fisher Scientific (Inst); Turnstone Bio (Inst)
(OPTIONAL) Uncompensated Relationships - North American Neuroendocrine Tumor Society
 
Fang-Shu Ou
No Relationships to Disclose
 
Nguyen Tran
Honoraria - Helsinn Therapeutics (Inst); QED Therapeutics (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); QED Therapeutics (Inst); TEMPUS (Inst)
Research Funding - Exact Sciences